Literature DB >> 7357546

L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line.

L W Brox, B Gowans, A Belch.   

Abstract

L-Phenylalanine mustard (melphalan) induced a time- and concentration-dependent arrest of cycling RPMI 6410 cells in the G2 phase of the cell cycle as evidenced by flow cytofluorometry. A melphalan exposure of 1 microgram/ml for 1 hr caused a temporary G2 blockage which was overcome by 48 hr. Higher concentrations or longer exposures lead to irreversible blockages. Melphalan caused DNA cross-linking which was monitored by the alkaline elution method. The cross-linking was shown to be between DNA and protein. The degree of DNA cross-linking increased for approximately 4 hr after a 1-hr drug exposure of 1 microgram/ml. At 36 to 48 hr after the drug exposure, the cells overcame the G2 block and were dividing. The DNA cross-links have apparently been repaired as they are no longer detected by alkaline elution. The extent of melphalan cross-linking was dependent on both drug dosage and exposure time. Using a culture medium lacking amino acids, it was shown that melphalan uptake into RPMI 6410 cells was inhibited by leucine, isoleucine, or glutamine. The increased uptake of melphalan and the increased cross-linking in amino acid-deficient media were reduced by readdition of the aforementioned amino acids.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357546

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.

Authors:  R Shepherd; K R Harrap
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

4.  Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents.

Authors:  M Smellie; L R Kelland; D E Thurston; R L Souhami; J A Hartley
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.